Clinical Trial Update: Effect of CER-001 on Plaque Volume in Homozygous Familial Hypercholesterolemia (HoFH) Subjects [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating CER-001 for reducing plaque volume in adults with Homozygous familial hypercholesterolemia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Homozygous Familial Hypercholesterolemia

Drugs mentioned

• CER-001

Snippet

Sponsor: Cerenis Therapeutics, SA | Conditions: Homozygous Familial Hypercholesterolemia | Phase 2 | Status: COMPLETED